H.C. Wainwright initiated coverage of Pelthos Therapeutics (PTHS) with a Buy rating and $60 price target Pelthos is a commercial stage biopharma company which launched its first drug, Zelsuvmi in July, the analyst tells investors in a research note. The firm says Zelsuvmi is the first and only at-home treatment indicated for the treatment of molluscum contagiosum, a “large, underserved market.” H.C. Wainwright expects continued commercial execution and outperformance on Zelsuvmi to drive share upside in the near term.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS:
- Pelthos Therapeutics initiated with a Buy at Roth Capital
- Pelthos Therapeutics price target raised to $57 from $50 at Oppenheimer
- Pelthos Therapeutics price target raised to $75 from $60 at Alliance Global
- Pelthos Therapeutics Reports Promising Q3 2025 Results
- Pelthos Therapeutics Earnings Call Highlights Growth and Challenges